Matches in Wikidata for { <http://www.wikidata.org/entity/Q66407398> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q66407398 description "clinical trial" @default.
- Q66407398 description "ensayu clínicu" @default.
- Q66407398 description "klinisch onderzoek" @default.
- Q66407398 description "клінічне випробування" @default.
- Q66407398 name "Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome" @default.
- Q66407398 name "Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome" @default.
- Q66407398 type Item @default.
- Q66407398 label "Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome" @default.
- Q66407398 label "Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome" @default.
- Q66407398 prefLabel "Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome" @default.
- Q66407398 prefLabel "Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome" @default.
- Q66407398 P1050 Q66407398-D1F14372-99BA-426B-81C8-9F9A292B6B75 @default.
- Q66407398 P1050 Q66407398-FF9F245A-7C39-4A19-8876-B84B3D778406 @default.
- Q66407398 P1132 Q66407398-5CE528FD-F0B3-4B5E-9DBB-BDFEBDA8073C @default.
- Q66407398 P1476 Q66407398-691B55AE-D4CF-4784-8A15-1647AA0AD3E3 @default.
- Q66407398 P17 Q66407398-A73D8BB1-F6A2-404D-B49B-D3C46DA6E736 @default.
- Q66407398 P2899 Q66407398-207E3327-BF80-4B0D-8313-243A14B580D0 @default.
- Q66407398 P3098 Q66407398-25A698BE-01E5-432E-87C2-4B84DFBE6F8E @default.
- Q66407398 P31 Q66407398-45A786C4-BBC1-4768-B44C-647F12CFBDBC @default.
- Q66407398 P4844 Q66407398-7A99F5F8-39B8-4B56-B70E-9C724C104872 @default.
- Q66407398 P4844 Q66407398-A328DCA1-317F-4CF8-87EE-D809A7194DCB @default.
- Q66407398 P580 Q66407398-760CD1F1-FC1B-4490-8182-3AEB0EB6E8E9 @default.
- Q66407398 P582 Q66407398-C3F6DFD1-9545-4B97-9515-3EBE505614FA @default.
- Q66407398 P6099 Q66407398-6A278F49-891D-462C-8121-BABC83B59068 @default.
- Q66407398 P8363 Q66407398-0CE66B52-037F-4DB5-8A01-AC7A65FC1CA9 @default.
- Q66407398 P1050 Q179630 @default.
- Q66407398 P1050 Q29496 @default.
- Q66407398 P1132 "+40" @default.
- Q66407398 P1476 "Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)" @default.
- Q66407398 P17 Q30 @default.
- Q66407398 P2899 "+18" @default.
- Q66407398 P3098 "NCT02649764" @default.
- Q66407398 P31 Q30612 @default.
- Q66407398 P4844 Q180983 @default.
- Q66407398 P4844 Q185916 @default.
- Q66407398 P580 "2016-05-04T00:00:00Z" @default.
- Q66407398 P582 "2021-05-31T00:00:00Z" @default.
- Q66407398 P6099 Q5452194 @default.
- Q66407398 P8363 Q78089383 @default.